Prior to going on Tysabri I did research, read the clinical trials and thought I was making an educated decision. If I had the info, I still would have gone on the medicine. I would have stopped and had this removed prior to my second infusion. It may not have metasized, it may have.
Patient levels for Tysabri are nowhere close to where Biogen had predicted they would be at this point in time.
Their other star drug, Avonex, is losing market share monthly.
There is no way on earth that Biogen is going to caution doctors about the possible risk of melanoma with Tysabri because of the possible impact on revenues. It is unfortunate but the reality when it comes to how big pharma operates. It is all about the revenue and share prices.
I hope your problem was caught in time and that you are OK. MS patients don't need other medical problems on top of what they have to go through on a daily basis.